Literature DB >> 12051885

Down-regulation of p27 is associated with malignant transformation and aggressive phenotype of cervical neoplasms.

Lee-Wen Huang1, Shiouh-Lirng Chao, Jiann-Loung Hwang, Yuh-Yu Chou.   

Abstract

OBJECTIVES: p27Kip1 (p27) is a member of the cyclin-dependent kinase inhibitor family. The level of p27 protein expression decreases during tumor development and progression in some epithelial tumors. To identify the potential implications of the p27 gene in the development of cervical carcinoma and explore the clinical importance of change in gene expression, we assessed the level of p27 protein in precancerous lesions and carcinomas of the cervix.
METHODS: In our study, 20 low-grade squamous intraepithelial lesions (LSIL), 35 high-grade squamous intraepithelial lesions (HSIL), 12 microinvasive carcinomas, and 103 invasive carcinomas were evaluated. The expression of p27 was studied by immunohistochemistry using a monoclonal antibody specific for the protein.
RESULTS: p27 was expressed in all samples of normal epithelium, LSIL, and HSIL, and the mean values of expression were 55.1, 52.8, and 45.4%, respectively. Conversely, the expression of p27 was significantly reduced in microinvasive (15.9%) and invasive carcinomas (11.2%). Furthermore, loss of p27 expression was significantly associated with lymph node metastasis (P = 0.009). However, p27 down-regulation had no influence on overall survival using univariate analysis.
CONCLUSIONS: The trend of reduced p27 expression in microinvasive and invasive carcinomas suggests that down-regulation of p27 expression is strongly linked to neoplastic transformation of cervical epithelium, and inactivation of p27 may be an early event in cervical carcinogenesis. Moreover, loss of p27 expression was related to lymph node metastasis in cervical carcinoma. These results imply that inactivation of p27 is associated with highly aggressive phenotype of cervical carcinoma.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12051885     DOI: 10.1006/gyno.2002.6666

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  7 in total

Review 1.  Aberrant cell cycle regulation in cervical carcinoma.

Authors:  Young Tae Kim; Min Zhao
Journal:  Yonsei Med J       Date:  2005-10-31       Impact factor: 2.759

2.  Necrosis related HIF-1alpha expression predicts prognosis in patients with endometrioid endometrial carcinoma.

Authors:  Laura M S Seeber; Nicole Horrée; Petra van der Groep; Elsken van der Wall; René H M Verheijen; Paul J van Diest
Journal:  BMC Cancer       Date:  2010-06-19       Impact factor: 4.430

3.  Decreased p21 expression in HPV-18 positive cervical carcinomas.

Authors:  Lee-Wen Huang; Kok-Min Seow; Chin-Cheng Lee; Yu-Hung Lin; Hun-Shan Pan; Heng-Ju Chen
Journal:  Pathol Oncol Res       Date:  2009-08-06       Impact factor: 3.201

4.  DEK proto-oncogene expression interferes with the normal epithelial differentiation program.

Authors:  Trisha M Wise-Draper; Richard J Morreale; Teresa A Morris; Rachael A Mintz-Cole; Elizabeth E Hoskins; Scott J Balsitis; Nader Husseinzadeh; David P Witte; Kathryn A Wikenheiser-Brokamp; Paul F Lambert; Susanne I Wells
Journal:  Am J Pathol       Date:  2008-11-26       Impact factor: 4.307

5.  Association between p21 Ser31Arg polymorphism and the development of cervical lesion in women infected with high risk HPV.

Authors:  Géssica Lima; Erinaldo Santos; Hildson Angelo; Micheline Oliveira; Sandra Heráclio; Fernanda Leite; Celso de Melo; Sergio Crovella; Maria Maia; Paulo Souza
Journal:  Tumour Biol       Date:  2016-02-17

6.  The possible role of cell cycle regulators in multistep process of HPV-associated cervical carcinoma.

Authors:  Abeer A Bahnassy; Abdel Rahman N Zekri; Maha Saleh; Mohammad Lotayef; Manar Moneir; Osama Shawki
Journal:  BMC Clin Pathol       Date:  2007-05-24

7.  Promoter hypermethylation of KLF4 inactivates its tumor suppressor function in cervical carcinogenesis.

Authors:  Wen-Ting Yang; Peng-Sheng Zheng
Journal:  PLoS One       Date:  2014-02-14       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.